Abstract 1180TiP
Background
Anti–PD-1 therapy (eg, pembro, nivo) in the adjuvant setting is one of the standard-of-care regimens for patients with BRAF-mutant metastatic melanoma. However, a significant proportion of patients have a limited or no response to anti–PD-1 therapy. Therefore, there is an unmet need to determine the optimal treatment sequence in patients resistant to anti–PD-1 therapy. BRAF + MEK inhibitors (eg, enco + bini) are also treatment options for BRAF-mutant metastatic melanoma. This phase II trial will evaluate the combination of enco + bini + pembro vs nivo + ipi in participants (pts) with advanced BRAF-mutant melanoma who progressed during or after anti–PD-1 therapy.
Trial design
PORTSIDE is an international open-label trial recruiting approximately 150 pts. Pts will be randomized 1:1 to receive either enco 450 mg (QD, PO), bini 45 mg (BID, PO), and pembro 200 mg (Q3W, IV) in 21-day cycles or 4 cycles of induction with nivo 1 mg/kg (Q3W, IV) and ipi 3 mg/kg (Q3W, IV) followed by maintenance with nivo 480 mg (Q4W, IV). Pts will be stratified by type of PD-1 resistance (primary vs secondary) and baseline lactate dehydrogenase level (above vs below the upper limit of normal). Pts must be ≥18 years old with histologically confirmed unresectable locally advanced or metastatic cutaneous BRAF V600E/K-mutant melanoma (per AJCC 8th edition) with ≥1 measurable lesion per RECIST v1.1. Pts must have received only 1 prior line of systemic therapy for melanoma and have confirmed disease progression per RECIST v1.1, either during or after receipt of an anti-PD1 therapy. Pts must have an ECOG PS of 0 or 1 and adequate organ function. Pts who discontinued prior anti–PD-1 therapy due to toxicity or who may not tolerate combination therapy are not eligible. Pts must not have previously participated in the STARBOARD study (NCT04657991) or received prior treatment with BRAF and/or MEK inhibitors, ipi, combined immunotherapy with anti-PD1/L1 treatment, or any other anticancer agents. The primary endpoint is objective response rate; key secondary endpoints are progression-free and overall survival.
Clinical trial identification
Editorial acknowledgement
Editorial/medical writing support was provided by Darren Chow, MSc, of Meditech Media and was funded by Pfizer.
Legal entity responsible for the study
Pfizer, Inc.
Funding
This trial was sponsored by Pfizer in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
D. Schadendorf: Financial Interests, Personal, Invited Speaker: BMS, Novartis, MSD, Roche, Merck Serono, Sanofi, Novartis, BMS, MSD; Financial Interests, Personal, Advisory Board: BMS, Novartis, MSD, Immunocore, Pierre Fabre, Sanofi-Regeneron, Pfizer, Philogen, Neracare; Financial Interests, Institutional, Invited Speaker: Novartis, BMS, MSD, Pierre Fabre, Sanofi, Philogen; Financial Interests, Institutional, Research Grant: BMS, MSD; Non-Financial Interests, Member of Board of Directors: EORTC-MG. R. Dummer: Financial Interests, Personal, Other, Consulting and/or advisory role: Novartis, Merck Sharp & Dohme (MSD), Bristol Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, CatalYm, Second Genome, Regeneron, Alligator, MaviVAX SA, touchIME, T3 Pharma, Pfizer, Simcere. A. Ribas: Financial Interests, Personal, Advisory Board, Honoraria for consulting: Amgen, AstraZeneca, Merck, Novartis, Jazz; Financial Interests, Personal, Advisory Board, Member of the Scientific Advisory Board: Apricity, Appia, Arcus, Compugen, Immpact, Lutris, MapKure, Merus, PACT Pharma, Synthekine, Tango; Financial Interests, Personal, Member of Board of Directors, Member of the Board of Directors: Arcus, Lutris, PACT Pharma; Financial Interests, Personal, Stocks/Shares, Stock ownership: 4C Biomed, Apricity, Appia, Arcus, Compugen, Highlight, ImaginAb, Immpact, ImmuneSensor, Inspirna, Isoplexis, Lutris, MapKure, Merus, Pluto, Synthekine, PACT Pharma, Tango, Advaxis, CytomX, RAPT, Kite-Gilead; Financial Interests, Personal, Invited Speaker: Arsenal Bio; Financial Interests, Institutional, Funding: Agilent, Bristol Myers Squibb; Non-Financial Interests, Advisory Role, Member of the scientific advisory board: Highlight, ImmuneSensor, Inspirna, Pluto. C. Robert: Financial Interests, Personal, Other, Consultancy fees: BMS, Roche, Pierre Fabre, Novartis, Sanofi, MSD, AstraZeneca, Pfizer. R.J. Sullivan: Financial Interests, Personal, Advisory Board: Merck, Novartis, Bristol Myers Squibb, Eisai, Iovance, OncoSec, Pfizer, Replimune, Marengo; Financial Interests, Personal, Royalties: Up-To-Date; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Invited Speaker: GSK, Pfizer, Sanofi, Moderna, Roche-Genentech, BioMed Valley Discoveries, Astex, Compugen, Beigene, Novartis, Rubius, Alkermes, Simcha Therapeutics, OnKure, Marengo, Synthekine. A. King: Other, Institutional, Full or part-time Employment: Pfizer, Inc. A. Polli: Financial Interests, Institutional, Full or part-time Employment: Pfizer, Inc. A. di Pietro: Other, Institutional, Full or part-time Employment: Pfizer, Inc. P.A. Ascierto: Financial Interests, Personal, Other, Consultant and Advisory Role: BMS, Roche Genentech, MSD, Novartis, Merck Serono, Pierre Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Nektar, Boehringer Ingelheim, Regeneron; Financial Interests, Personal, Other, Consultant and Advisory Role, Travel support: Pfizer/Array; Financial Interests, Personal, Other, Consultant Role: Italfarmaco; Financial Interests, Personal, Other, Advisory Role: Eisai, Seagen; Financial Interests, Personal, Other, Consultant Role: Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore; Financial Interests, Personal, Other, Consultant role and travel support: Bio-AI Health; Financial Interests, Personal, Other, Consultant role: Medicenna; Financial Interests, Personal, Advisory Board, Consultant and Advisory Role: iTeos; Financial Interests, Personal, Advisory Board, Consultant and Advisory role: ValoTx; Financial Interests, Personal, Advisory Board, Consultant and Advisor role. Travel support: Replimune; Financial Interests, Personal, Advisory Board, Advisor role: Bayer; Financial Interests, Institutional, Funding, Clinical Trial: Pfizer/Array, Roche Genentech, Sanofi; Financial Interests, Personal, Advisory Board: Erasca; Financial Interests, Institutional, Funding, Clinical trial and translational research: BMS; Non-Financial Interests, Leadership Role, President since 2010: Fondazione Melanoma Onlus Italy; Non-Financial Interests, Leadership Role, President since 2014: Campania Society of ImmunoTherapy of Cancer (SCITO) Italy; Non-Financial Interests, Other, Member of Steering Committee since 2016: Society for Melanoma Research (SMR); Non-Financial Interests, Member of Board of Directors, November 2017 - December 2021: Society for Immunotherapy of Cancer (SITC); Non-Financial Interests, Member: ASCO, SITC, EORTC Melanoma Cooperative Group, SMR, AIOM.
Resources from the same session
1181TiP - BEPCOME-MB: Treatment of BRAFV600 mutated melanoma brain metastases with encorafenib + binimetinb + pembrolizumab with or without stereotactic radiosurgery
Presenter: Philippe Saiag
Session: Poster session 13
1188P - Landscape of Delta-like-ligand 3 (DLL3) expression across neuroendocrine neoplasms (NENs)
Presenter: Anthony Crymes
Session: Poster session 13
1189P - Mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN): Characterization of the genomic and pathological profile
Presenter: Annabella Di Mauro
Session: Poster session 13
1191P - TTF-1 expression in lung neuroendocrine tumors (NET): A gender-related biomarker
Presenter: Anna La Salvia
Session: Poster session 13
1192P - Smoking adversely affects survival of metastatic lung carcinoid patients: Analysis of a large international audit
Presenter: Sara Valpione
Session: Poster session 13
1193P - Evaluation of treatment appropriateness in patients submitted to surgery for non-functioning pancreatic neuroendocrine tumors (NF-PanNETs)
Presenter: Anna Battistella
Session: Poster session 13
1194P - Do metastatic appendiceal NETs ever develop metachronously after appendectomy or right hemicolectomy?
Presenter: Taymeyah Al-Toubah
Session: Poster session 13
1195P - Neuroendocrine Tumors (NETs): How Big Data (BD) techniques applied to Electronic Health Records (EHR) can improve our understanding of this patient population
Presenter: Jorge Hernando
Session: Poster session 13
1196P - Regional lymph node metastasis risk factors for rectal neuroendocrine tumors: A population-based study
Presenter: Dan Cao
Session: Poster session 13
1197P - Somatostatin analogs or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors
Presenter: Maria Grazia Maratta
Session: Poster session 13